In this episode of Life Science Insights 360, I'm delighted to welcome Ivanna Rosendal, Vice President of Business Digitalization, a global leader driving digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.Beyond her executive leadership role, Ivanna is also an author, podcast host, and stand-up comedian, bringing a unique perspective on innovation, leadership, organizational change, and the human side of digital transformation. Drawing from her extensive experience, she shares how life sciences organizations can successfully navigate technological disruption while keeping people, patients, and purpose at the center of innovation.Our conversation explores the future of AI-powered drug development, digital transformation, decentralized clinical trials, leadership in highly regulated industries, and how emerging technologies are reshaping the future of healthcare.## Key Topics Discussed- Ivanna Rosendal's career journey and leadership in business digitalization.- Driving enterprise-wide digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.- The biggest leadership challenges in implementing digital transformation within highly regulated life sciences companies.- How artificial intelligence is transforming clinical development and accelerating innovation.- The importance of data quality, interoperability, and connected digital ecosystems.- Why digital transformation initiatives succeed—or fail—and lessons for organizational change.- The future of decentralized and hybrid clinical trials.- Leveraging real-world data and real-world evidence to improve clinical decision-making.- Emerging technologies including AI agents, predictive analytics, digital twins, and intelligent automation.- Building cultures that embrace innovation, continuous learning, and change.- Leadership lessons for developing the next generation of life sciences professionals.- Balancing executive leadership with writing, podcasting, and stand-up comedy, and how storytelling and humor strengthen communication and leadership.## Episode Highlights- Expert insights into digital transformation across the life sciences industry.- A forward-looking discussion on AI, data strategy, and the future of clinical development.- Practical leadership advice for driving organizational change and innovation.- Perspectives on emerging technologies that are reshaping drug development and healthcare.- An inspiring conversation about leadership, creativity, communication, and the value of bringing authenticity and humor into the workplace.Whether you're a life sciences executive, digital transformation leader, clinical research professional, healthcare innovator, technology enthusiast, or aspiring leader, this episode offers valuable insights into the strategies, technologies, and leadership principles shaping the future of life sciences.

In this episode of the Life Science Insights Podcast , I'm delighted to welcome Dr. Faisal Mehmud, Chief Medical Officer of Medicus Pharma , a clinical-stage biotechnology company focused on developing innovative therapies for oncology and other high unmet medical needs.With an exceptional career spanning global pharmaceutical leaders including Sanofi, Novartis, Bristol Myers Squibb, Pfizer, and GSK , Dr. Mehmud shares his journey through clinical development, medical leadership, and drug innovation. We explore how Medicus Pharma is advancing novel therapeutic approaches for skin cancer and prostate cancer, and discuss the future of precision oncology, artificial intelligence, and patient-centered drug development.Our conversation highlights the company's lead programs, SkinJect and Teverelix , along with broader industry trends that are transforming clinical research, oncology, and the development of next-generation therapies.## Key Topics Discussed- Dr. Faisal Mehmud's career journey and leadership across global pharmaceutical companies.- Medicus Pharma's mission and its approach to developing innovative oncology therapies.- The science behind SkinJect , a dissolvable microneedle patch designed for localized treatment of skin cancer.- The advantages of localized drug delivery compared with traditional systemic chemotherapy.- Key insights from the Phase 2 clinical study of SkinJect.- An overview of Teverelix and its potential role in treating prostate cancer.- The importance of cardiovascular safety in oncology drug development.- Emerging trends improving the efficiency of clinical trials.- How artificial intelligence and digital technologies are transforming clinical development.- Medicus Pharma's partnership strategy and the value of advancing programs through Phase 2 before strategic collaborations.- The evolution of precision oncology and innovation across the pharmaceutical industry.- Leadership insights, career advice for the next generation of physicians and scientists, and the future outlook for biotechnology innovation.## Episode Highlights- Expert insights into the future of precision oncology and innovative cancer therapeutics.- A deep dive into SkinJect and Teverelix, two promising programs addressing significant unmet medical needs.- Perspectives on AI, digital transformation, and the future of clinical development.- Leadership lessons from decades of experience across some of the world's leading pharmaceutical companies.- A forward-looking discussion on biotechnology innovation, strategic partnerships, and improving outcomes for cancer patients.Whether you're a biotechnology professional, oncologist, clinical researcher, life sciences executive, investor, or healthcare innovator, this episode offers valuable insights into the technologies, strategies, and scientific advances shaping the future of cancer care and precision medicine.

In this episode of the Life Science Insights Podcast, I'm delighted to welcome Dr. John Craighead, CEO of Syntax Bio, a synthetic biology company advancing the next generation of programmable stem cell therapies.With more than 20 years of leadership experience across biotechnology, corporate strategy, and life sciences, Dr. Craighead has held executive leadership roles at organizations including GRAIL, Sanofi, Atara Biotherapeutics, HALO Precision Diagnostics, and now Syntax Bio. He shares his journey from cell biology research to leading innovative biotechnology companies and discusses how scientific innovation, strategic partnerships, and advanced manufacturing are shaping the future of regenerative medicine.Our conversation explores Syntax Bio's mission to engineer programmable stem cell therapies, the challenges of scaling cell-based therapeutics, and the role of synthetic biology, computational biology, and artificial intelligence in accelerating the next generation of precision medicine. We also discuss the company's strategic collaboration with Applied StemCell, biotechnology funding, and the future of programmable cell engineering.## Key Topics Discussed* Dr. John Craighead's career journey from cell biology research to biotechnology leadership.* Leadership lessons from GRAIL, Sanofi, Atara Biotherapeutics, and Syntax Bio.* Syntax Bio's mission to develop programmable stem cell therapies.* The scientific and manufacturing challenges of stem-cell-based therapeutics.* Improving the speed, consistency, and scalability of therapeutic cell manufacturing.* The strategic collaboration between Syntax Bio and Applied StemCell and its impact on innovation.* The growing role of synthetic biology in advancing regenerative medicine.* How computational biology and artificial intelligence are accelerating therapeutic discovery and development.* Balancing personalized therapies with scalable manufacturing.* Building high-performing biotechnology organizations and leading multidisciplinary teams.* The importance of strategic partnerships and investment in advancing biotechnology innovation.* Trends shaping the future of synthetic biology, regenerative medicine, and programmable cell therapies.## Episode Highlights* Insights into the future of programmable stem cell therapies and regenerative medicine.* Expert perspectives on synthetic biology and next-generation therapeutic innovation.* A discussion on manufacturing challenges and scaling advanced cell therapies.* How AI, computational biology, and automation are transforming biotechnology research and development.* Leadership lessons on innovation, strategy, fundraising, and building world-class biotechnology companies.* A forward-looking conversation on the future of precision medicine and engineered cell therapies.Whether you're a biotechnology professional, life sciences executive, researcher, investor, entrepreneur, or student, this episode offers valuable insights into one of the fastest-evolving areas of modern medicine and the technologies that are redefining the future of healthcare.

In this episode of the Life Science Insights Podcast, we sit down with Jimmy Bechtel, Chief Strategy & Site Solutions Officer (CSSO) at the Society for Clinical Research Sites (SCRS), to explore the evolving landscape of clinical research and the critical role research sites play in advancing innovation, improving patient outcomes, and driving more efficient clinical trials.Jimmy shares his perspective on the challenges facing research sites today, the growing importance of site sustainability, and how technology, AI, and stronger collaboration between sponsors, CROs, and research sites are shaping the future of clinical research. We also discuss how patient-centric approaches, operational excellence, and digital transformation are redefining the clinical trial ecosystem.Key Topics DiscussedJimmy Bechtel's professional journey into clinical research and site managementThe meaning of site success in today's clinical trial environmentMajor operational challenges facing clinical research sitesThe growing importance of long-term site sustainabilityStrengthening collaboration between research sites, sponsors, and CROsLeveraging technology to improve site efficiency and reduce administrative burdenThe evolution of decentralized and hybrid clinical trialsStrategies for improving patient engagement and retentionAddressing workforce shortages in clinical researchThe impact of AI and automation on site operationsImproving interoperability and workflow integrationAdvancing diversity, accessibility, and inclusion in clinical trialsBuilding resilient and sustainable research programsEmerging trends shaping the next generation of clinical research sitesEpisode Highlights✔ Expert insights into the challenges and opportunities facing modern clinical research sites✔ Perspectives on AI, digital transformation, and technology-enabled clinical trials✔ Practical strategies for improving site sustainability and operational efficiency✔ A discussion on patient-centric trial design, accessibility, and engagement✔ A forward-looking vision for the future of clinical research and patient careSubscribe to the Life Science Insights Podcast for more conversations with industry leaders, innovators, and experts shaping the future of clinical research, biotechnology, and healthcare.#LifeScienceInsights #ClinicalResearch #ClinicalTrials #SCRS #JimmyBechtel #ResearchSites #SiteManagement #PatientCentricity #DecentralizedTrials #AIInHealthcare #DigitalHealth #Biotechnology #HealthcareInnovation #ClinicalOperations #FutureOfClinicalResearch

In this episode of the Life Science Insights Podcast, we sit down with Mark Van Zee, Founder and CEO of Saku Biosciences, to explore the future of scalable biology and how innovations in cell line development are transforming modern biomanufacturing. Mark shares his journey from bioengineering research to entrepreneurship and explains why the greatest challenge facing biotechnology today is not scientific discovery—but scaling innovation to deliver real-world impact.From breakthrough PicoShell® technology to the future of automation, sustainable biomanufacturing, and next-generation cell engineering, this conversation examines how advanced technology platforms are accelerating drug development, improving manufacturing efficiency, reducing costs, and expanding global access to innovative therapies.Key Topics DiscussedMark Van Zee's journey from bioengineering research to founding Saku BiosciencesWhy biotechnology faces a scalability challenge rather than an R&D challengeUnderstanding PicoShell® technology and its applicationsAccelerating cell line development through advanced screening technologiesThe impact of high-performing producer cells on biomanufacturing efficiencyKey factors biopharma companies consider when evaluating new technology platformsThe role of automation and advanced screening in eliminating development bottlenecksStrengthening biomanufacturing supply chains through modern technologiesSustainable biotechnology and the importance of alternative feedstocksReducing downstream processing costs through improved cell engineeringChallenges and opportunities in scaling biotechnology innovationsBalancing scientific innovation with fundraising and commercializationLessons learned while building Saku BiosciencesThe future of scalable biology across healthcare, food, and industrial biotechnologyEpisode Highlights✔ Why scaling remains one of biotechnology's greatest challenges✔ How PicoShell® technology is transforming cell line development✔ The growing role of automation in modern biomanufacturing✔ Strategies for building more resilient and sustainable biotech supply chains✔ Insights into commercializing breakthrough biotechnology platforms✔ A forward-looking vision for scalable biology and its impact across healthcare and industrySubscribe to the Life Science Insights Podcast for more conversations with innovators, entrepreneurs, and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SakuBiosciences #Biotechnology #Biomanufacturing #CellLineDevelopment #Bioprocessing #Biopharma #SyntheticBiology #LifeSciences #HealthcareInnovation #Bioengineering #Automation #ScalableBiology #BiotechPodcast #DrugDevelopment

In this episode of the Life Science Insights Podcast, we sit down with Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, to explore how artificial intelligence and causal machine learning are transforming clinical development. Dr. Pryluk explains how AI-driven trial optimization is making clinical trials faster, smarter, and more efficient—while reducing costs, minimizing risk, and improving the probability of success.We discuss PhaseV's innovative approach to adaptive, causal, and data-driven clinical development, the growing role of AI in clinical decision-making, and how next-generation technologies are helping sponsors design more efficient, personalized, and successful clinical trials.Key Topics DiscussedUnderstanding adaptive, causal, and data-driven clinical developmentHow causal machine learning differs from traditional AI approachesDefining AI-driven clinical trial optimization in practical termsHow PhaseV's Trial Optimizer enhances trial efficiency while reducing costsBalancing statistical rigor with real-world clinical trial constraintsReal-world examples of AI-driven trial optimizationMajor inefficiencies in today's clinical trial ecosystemUsing AI and machine learning to de-risk drug developmentRegulatory perspectives on AI-enabled clinical trial designBuilding trust, transparency, and interpretability in AI-driven decision-makingAddressing data variability and bias across diverse patient populationsLeadership lessons from building and scaling an AI-driven healthcare companyBuilding multidisciplinary teams across AI, biology, and clinical researchThe future of clinical trials: smaller, faster, and more personalized studiesThe long-term impact of AI on the economics of drug developmentEpisode Highlights✔ A clear explanation of causal machine learning and why it matters✔ How AI is optimizing trial design, patient selection, and clinical outcomes✔ Strategies for reducing clinical trial costs, timelines, and development risk✔ The importance of explainable and trustworthy AI in clinical decision-making✔ Leadership insights from building and scaling an AI-first healthcare company✔ A forward-looking vision for the future of AI-powered clinical developmentSubscribe to the Life Science Insights Podcast for more conversations with innovators, researchers, and industry leaders advancing the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #PhaseV #ArtificialIntelligence #ClinicalTrials #DrugDevelopment #MachineLearning #CausalAI #ClinicalResearch #PrecisionMedicine #Biotechnology #HealthcareInnovation #DigitalHealth #LifeSciences #AIInHealthcare #BiotechPodcast

In this episode of the Life Science Insights Podcast, we sit down with Karsten Eastman, CEO and Co-founder of Sethera Therapeutics, to explore how innovative enzyme-based technologies are transforming drug discovery. Karsten shares the inspiration behind founding Sethera, the scientific challenges the company is addressing, and how its unique platform is enabling the discovery of next-generation peptide therapeutics for difficult-to-treat diseases.We discuss the power of enzymes in drug discovery, the promise of enzymatically constrained peptides, the role of AI and data in modern biotechnology, and the future of peptide-based medicines.Key Topics Discussed:The inspiration behind founding Sethera TherapeuticsThe unmet needs in drug discovery that Sethera aims to addressAn overview of Sethera's technology platform and missionWhat differentiates Sethera from other biotech companiesUnderstanding enzyme-enabled drug discovery in simple termsWhy enzymes are powerful tools for creating novel medicinesThe science and potential of enzymatically constrained peptidesAddressing hard-to-treat diseases and previously undruggable targetsDiscovering therapies for previously inaccessible biological targetsHow Sethera identifies, screens, and optimizes new moleculesThe role of data, AI, and machine learning in drug discoveryChallenges and lessons learned while building a biotechnology companyBalancing scientific innovation with business growth and executionBuilding high-performing, multidisciplinary biotech teamsEmerging trends shaping the future of biotechnology and drug discoveryThe future impact of peptide-based therapeutics on healthcareEpisode Highlights✔ The founding story behind Sethera Therapeutics✔ A simple explanation of enzyme-enabled drug discovery✔ Why constrained peptides represent an exciting new therapeutic class✔ How biotechnology is expanding the range of druggable targets✔ The growing role of AI, data, and advanced platforms in drug discovery✔ A vision for the future of precision medicine and patient careSubscribe to the Life Science Insights Podcast for more conversations with innovators and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SetheraTherapeutics #DrugDiscovery #Biotechnology #PeptideTherapeutics #Biotech #LifeSciences #PrecisionMedicine #DrugDevelopment #Enzymes #AIinBiotech #HealthcareInnovation #Biopharma #LifeSciencePodcast #futureofmedicine

In this episode of the Life Science Insights Podcast, we explore the future of MedTech collaboration, innovation, and community-driven growth with , Co-Founder of and White Lamb Medtech Consulting.In a conversation about her journey building platforms that connect MedTech professionals, strengthen industry partnerships, and support meaningful collaboration across the healthcare ecosystem. With over a decade of experience in global medical devices and regulatory strategy, she shares deep insights into navigating complex regulatory landscapes and scaling innovation across regions.

Key Topics DiscussedThe episode explores the founding vision behind indieMedTech and the industry gaps it aims to solve, along with the meaning of building a true “community” in MedTech. Holly discusses how regulatory expectations vary across global markets and how companies can successfully navigate these complexities.Additional themes include fostering authentic collaboration in a competitive industry, building successful MedTech partnerships, and avoiding common mistakes when scaling globally.

The conversation also highlights barriers to cross-stakeholder collaboration and how ecosystem alignment can accelerate innovation.Episode HighlightsThe inspiration and purpose behind founding indieMedTechThe evolving definition of community in MedTechStrategies for global regulatory navigationBuilding trust and collaboration in a competitive ecosystemCommon scaling mistakes in MedTech companiesSkills required for the next generation of MedTech professionalsHow professionals can build visibility and credibilityThe role of digital transformation in enabling innovationLeadership lessons from building a global MedTech networkMeasuring success through both growth and community impact.

The future of inclusive leadership in MedTechThe next 5–10 year outlook for MedTech ecosystemsAdvice for global expansion and cross-border innovationThe core message on collaboration driving MedTech progressThe episode closes with a reflection on the future of MedTech communities and how collaboration, shared learning, and ecosystem thinking will shape the next wave of healthcare innovation.

In this episode, we sit down with Levi S. Lian, CEO and Founder of Raycaster, to explore the critical evolution of document intelligence within the enterprise landscape. Drawing from a background that spans Stanford, Harvard Business School, and a deep-rooted family history in medicine, Levi shares his unique perspective on building AI-driven infrastructure that tackles one of the most persistent bottlenecks in modern business: the unstructured and complex document.

The conversation centers on the shift from traditional OCR and simple automation toward true document reasoning. We examine why scientific and technical documents pose such a significant challenge for legacy systems and how Raycaster is enabling organizations to move beyond mere data extraction to achieve actionable insights. We take a closer look at the strategic hurdles of enterprise AI adoption, discussing the vital balance between rapid product innovation and the rigorous demands of data security, accuracy, and regulatory compliance.

Listeners will gain a masterclass in the future of knowledge work and the ROI of modernizing document-heavy workflows. We discuss Levi’s journey as both a technical founder and an angel investor, offering insights into scaling AI infrastructure, overcoming misconceptions about machine intelligence, and the long-term risks facing industries that remain tethered to manual document processing.

In this episode, we are joined by Dr. Stanley T. Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to trace his profound transition from physician-scientist to biotech entrepreneur. With a career rooted in translational medicine and clinical development, Dr. Lewis provides an expert perspective on the arduous journey of moving innovation from the laboratory bench to the patient’s bedside. We dive into his mission to redefine precision oncology through Targeted Oncolytic Peptides (TOPs)—a novel modality designed to treat cancer with surgical precision while prioritizing the patient’s quality of life.

The conversation explores the strategic and scientific architecture required to build a therapeutics platform from scratch. We examine the lessons learned from Dr. Lewis’s previous success in bringing Trogarzo to market and how those cross-disciplinary insights from virology and infectious diseases are now being applied to solve unmet clinical needs in oncology. We take a closer look at the evolution of A28’s pipeline, discussing how the integration of biomarkers and advanced delivery systems is shaping the next generation of targeted cancer treatments.

Listeners will gain a rare look at the human-centered side of biotech leadership. We discuss the complexities of navigating regulatory milestones and financing, the importance of maintaining scientific rigor under the pressure of patient urgency, and why empathy remains the most critical component of medical innovation. Whether you are a scientist, a founder, or a healthcare leader, this episode offers a roadmap for balancing high-stakes operational execution with a steadfast focus on the human impact of medicine.